Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenip Plc Regulatory News (GNIP)

Share Price Information for Genip Plc (GNIP)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.00 (0.00%)
Bid:
4.50
Ask:
4.80
Spread: 0.30 (6.667%)
Market Cap: £1.19m
GNIP Live PriceLast checked at - London Stock Exchange

Intraday Genip Plc Share Chart

Technology Park Alliance

15 Oct 2025 07:00

RNS Number : 3763D
GenIP PLC
15 October 2025
 

 

 

 

15 October 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

Technology Park Alliance

 

GenIP Plc, a technology consultancy providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce a new collaboration with Pelotas Science Park (Parque Tecnológico de Pelotas) in Brazil, marking our first engagement with a technology park.

 

Pelotas Science Park serves as an innovation hub integrating the "quadruple helix": government, academia, industry, and civil society, and brings together incubators, coworking space, a regional startup network (Candy Valley), 63 resident and non-resident enterprises, and 23 partner institutions.

 

Under this partnership, GenIP will provide its suite of services to many of the park's tenant companies and incubated startups, guiding their decision-making process on which technologies are most viable for investment and commercialisation.

 

This agreement represents GenIP's efforts to lay the foundations for future growth through strategic alliances and partnerships, and aligns with the Company's strategic goal to diversify its client base beyond research organisations in order to increase the proportion of corporate clients to 45% of total clients.

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"Our collaboration with Pelotas Science Park represents an important milestone for GenIP as we expand our reach beyond universities to support entire innovation ecosystems. Science parks play a vital role in Technology Transfer by connecting researchers, startups, and industry partners, and we're proud to provide the analytical foundation that helps their tenant companies identify commercially viable technologies and attract investment. This partnership reflects our broader strategy to deepen engagement with industry and startup communities, bringing us closer to our goal of achieving 45% industry participation."

 

Vinicius Farías Campos, President at Pelotas Technology Park, commented:

 

"Through its Health and Biotechnology Innovation Hub, the Pelotas Technology Park is proud to collaborate with GenIP in applying AI-driven methodologies for technology assessment and valorization. This partnership accelerates the translation of scientific research into real-world applications, strengthening Southern Brazil's innovation ecosystem in health and biotechnology." 

 

 

For further information regarding GenIP, please visit www.genip.ai, or contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

AlbR Capital Limited (Broker) 

Colin Rowbury

Jon Belliss

Tel: +44 (0)20 7399 9427

cr@albrcapital.com 

Jb@albrcapital.com

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

Notes to Editors

 

About GenIP

 

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

Service

Description

Value Proposition

Invention Intelligence Product Suite

AI-powered market intelligence reports assessing the commercial potential of emerging technologies

Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy

Talent and Executive Search Services

Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership

De-risks scaling by aligning technical vision with proven executive capability

 

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

 

Organic ExpansionScale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

Service DeepeningEnhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

Strategic AcquisitionsPursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFFSFALEISELS
Date   Source Headline
24th Jun 20265:18 pmRNSResult of AGM
24th Jun 20267:00 amRNS-RGenIP Innovation Roundtable
29th May 20265:52 pmRNSTotal Voting Rights
27th May 20267:00 amRNSAudited Final Results FY25 and Notice of AGM
21st May 20267:00 amRNSNew Orders
5th May 202611:35 amRNSTR-1: Notification of major holdings
1st May 20267:00 amRNSShare Placing to raise £350,000 and TVR
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
31st Mar 20267:00 amRNS-RCommercial Update
10th Feb 20267:00 amRNS-RSales and Product Update
15th Jan 20267:00 amRNSCorporate Update
4th Dec 20257:00 amRNSOperational Update, Placing and TVR
21st Nov 20257:00 amRNS-RNew Report Orders From Repeat Clients
13th Nov 20257:00 amRNSTrading Statement
15th Oct 20257:00 amRNS-RTechnology Park Alliance
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
24th Sep 20257:00 amRNS-RStrategic Partnership
15th Sep 20257:00 amRNS-RStrategic Partnership
25th Jul 20257:00 amRNSTrading Statement
1st Jul 20257:00 amRNS-RGenIP Secures First UK Academic Clients
26th Jun 20255:07 pmRNSResult of AGM
10th Jun 20257:00 amRNSContract Win
4th Jun 20257:00 amRNSAudited Results for Period Ended 31 December 2024
2nd Jun 20256:27 pmRNSNotice of AGM
29th May 20257:00 amRNS-RBusiness Update
7th May 20257:00 amRNS-RGenIP to attend 2025 AUTM Canadian Region Meeting
1st May 20257:00 amRNS-RNew Product Launch
31st Mar 20255:34 pmRNSUnaudited Results to 31 December 2024
26th Mar 20257:00 amRNS-RContract Win
20th Mar 20257:00 amRNS$0.35m Contract Win
13th Mar 20257:00 amRNSCorporate Update & 2025 Outlook
11th Feb 20257:00 amRNS-RGenIP to Sponsor the AUTM 2025 Annual Meeting
3rd Dec 20245:29 pmRNSTR-1: Notification of major holdings
20th Nov 20247:00 amRNSCorporate Update
8th Oct 20247:00 amRNSCorporate Update
2nd Oct 20247:00 amRNSAdmission to Trading on AIM-First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.